CMS-121 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
CMS-121 is a lab-made cousin of fisetin, from the Salk Institute. In mouse models of Alzheimer's it improved memory and cut fat damage in the brain. It is still in animal safety testing, yet it is already sold as a research chemical.
Evidence grade for CMS-121: Animal or lab only. The rule: only animal or lab studies on this page. No study in people yet. The sum on this page: 2 animal studies, no human study. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
2 animal studies, no human study
2 effects reported, 2 unwanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
CMS-121 is a lab-made cousin of fisetin, a plant compound. It was built to reach the brain better. In mice with Alzheimer's-like disease it protected memory. It has never been tested in people, but sellers already offer it.
What people take it for
- Protecting memory with age.
- Lowering Alzheimer's risk.
What studies in people showed
Nobody has given it to a person. In mouse models of Alzheimer's, it kept memory intact and cut damage to fats in the brain. It still has to pass formal safety testing before any human trial can start.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- No human data at all, and animal safety testing is not finished.
- Sellers began selling it in 2026 anyway.
Where these come from: Everything here comes from the mouse studies on this page. We have no user reports.
My bottom line
The drug has not even cleared animal safety testing. Sleep, lifting and blood pressure control have far more brain evidence behind them than this.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 2 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is CMS-121?
CMS-121 is a lab-made cousin of fisetin, from the Salk Institute. In mouse models of Alzheimer's it improved memory and cut fat damage in the brain. It is still in animal safety testing, yet it is already sold as a research chemical.
CMS-121 was built to be stronger than fisetin and to get into the brain better. In mouse models of Alzheimer's, it kept memory intact and cut damage to fats in the brain. Part of that works through an enzyme that makes fatty acids. It has not been tested in people. It still has to pass formal safety testing before a human trial can start. Sellers began offering it under brand names in 2026 without any human data.
How does CMS-121 work?
It blocks an enzyme that makes fatty acids and cuts damage to fats in brain cells. In ageing brains, that seems to calm inflammation and keep brain cells' energy supply working.
The evidence, in charts
Fig. 1a · how many people
0people have taken this in any study cited here
0 people · 0 studies in people
What this page cites instead is 2 animal studies. None of them gave the compound to a person.
Counted from the list of sources on this page. We draw this chart only when a study in people is cited. An empty one is the answer, not a gap in the page.
Fig. 1b · evidence mix
None of the 2 sources here are studies in people.
- Animal study · done in animals2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2019 and 2024.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 321.4 Da
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for CMS-121, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Animal study2024CMS121, a Novel Drug Candidate for the Treatment of Alzheimer's Disease and Age-Related Dementia
In mice. A 2024 summary of how it did in mouse models and the testing steps left before any human trial.
Summarizes efficacy in mouse models and remaining preclinical steps.
- Animal study2019Acetyl-CoA metabolism and brain aging (Salk)
In mice. Background work on how it may work in the ageing brain.
Mechanistic background for CMS-121.
Common questions
Has CMS-121 been tested in people?
Not in any study cited here. CMS-121 is a lab-made cousin of fisetin, from the Salk Institute. In mouse models of Alzheimer's it improved memory and cut fat damage in the brain. It is still in animal safety testing, yet it is already sold as a research chemical.
What is the CMS-121 dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 2 animal studies, no human study
Is CMS-121 FDA-approved?
Animal or lab only; not approved
Is CMS-121 better than fisetin?
In mice, it is stronger. In people, neither has shown a memory benefit, and CMS-121 has no human data at all.